About Current Partnering
Current Partnering provides specialist life science deal intelligence, market analysis and executive-level partnering support.
For almost twenty years, we have tracked, classified and analysed collaboration, licensing, acquisition, commercialisation and financing activity across the pharmaceutical, biotechnology, diagnostics, medical technology and wider life science industries.
Our intelligence helps companies understand how deals are being structured, valued and negotiated, identify the organisations driving market activity, benchmark comparable transactions and make better-informed partnering and commercial decisions.
Current Partnering is built around three connected services.
Published Partnering Reports
Our portfolio of more than 60 specialist reports covers the principal therapy areas, technologies, deal types, stages of development and industry sectors involved in life science partnering.
Each report provides a structured and focused source of deal intelligence, including transaction summaries, financial terms, agreement structures, company activity and contract documents where available.
Clients use our reports to:
- identify comparable transactions;
- benchmark upfront payments, milestones, royalties and other deal terms;
- understand how agreements are structured;
- identify active dealmakers and potential partners; and
- assess partnering activity within a specific market.
Reports can be purchased individually or accessed through the Current Partnering Knowledge Center.
Custom Market Intelligence Analyses
Our Custom Market Intelligence Analyses provide a focused assessment of a defined life science market, technology, therapy area, product category or commercial opportunity.
They are designed for organisations that need to understand the wider market environment: where activity is increasing, which companies are leading, how technologies and commercial models are evolving, and where future opportunities may emerge.
Each analysis is shaped around the client’s specific market questions and may include:
- market and deal activity trends;
- leading companies and emerging participants;
- technology, product and therapy-area developments;
- competitive and commercial activity;
- development-stage and investment trends;
- deal structures and financial benchmarks;
- landmark transactions and market signals; and
- forward-looking observations on market direction.
These analyses are particularly relevant to market intelligence, product strategy, marketing, commercial strategy, portfolio planning and leadership teams.
The purpose is to explain what is happening across the wider market and what it may mean for future commercial opportunity.
Custom Executive Partnering Briefings
Our Custom Executive Partnering Briefings apply Current Partnering’s deal intelligence directly to a specific company, asset, product, technology platform, pipeline or partnering objective.
They are designed to support practical business development and licensing decisions, including how an opportunity should be positioned, which partners may be most relevant, how comparable deals have been structured and what financial terms may be achievable.
Each briefing is built around the client’s individual circumstances and may include:
- comparable transaction analysis;
- identification and prioritisation of potential partners;
- upfront, milestone and royalty benchmarking;
- assessment of licensing, collaboration and commercialisation structures;
- analysis of relevant counterparties and recent deal activity;
- positioning of an asset, platform or product within the current partnering landscape;
- valuation and negotiation considerations; and
- practical recommendations and next-step priorities.
These briefings are particularly relevant to business development, licensing, corporate development, valuation, alliance management and executive teams.
The purpose is to translate market and deal intelligence into company-specific partnering action.
Who We Serve
Current Partnering supports pharmaceutical, biotechnology, diagnostics and medical technology companies ranging from emerging ventures to established global organisations.
We also work with investors, advisers, universities, research organisations and specialist service providers requiring credible and commercially useful life science deal intelligence.
Our work is used by teams responsible for:
- business development and licensing;
- corporate and commercial strategy;
- market and competitive intelligence;
- valuation and deal benchmarking;
- alliance and portfolio management;
- commercialisation planning; and
- executive decision-making.
Why Current Partnering?
Current Partnering combines proprietary life science deal intelligence with experienced analyst interpretation and focused client-specific analysis.
Our clients use us to understand markets faster, benchmark opportunities with greater confidence, identify credible partners, strengthen deal positioning and support better commercial decisions.
Published deal intelligence. Custom market analysis. Company-specific partnering support.
Biopharma Research Ltd is the company behind the brands Current Partnering and Current Agreements.
Current Partnering is a division of Biopharma Research Ltd.
Biopharma Research Ltd. is a registered company in the UK - number: 8243684
